Specific immunotherapy of experimental myasthenia gravis in vitro and in vivo: The Guided Missile strategy

W. Sun, R. N. Adams, A. Miagkov, Y. Lu, H. S. Juon, D. B. Drachman

Research output: Contribution to journalArticlepeer-review

Abstract

Current immunotherapy of myasthenia gravis (MG) is often effective, but entails risks of infection and neoplasia. The "Guided Missile" strategy described here is designed to target and eliminate the individual's unique AChR-specific T cell repertoire, without otherwise interfering with the immune system. We genetically engineered dendritic cells to present AChR epitopes and simultaneously express Fas ligand in an ongoing EAMG model. In both in vitro and in vivo experiments, these engineered cells specifically killed AChR-responsive T cells without otherwise damaging the immune system. AChR antibodies were markedly reduced in the treated mice. Translation of this method to treat human MG is possible.

Original languageEnglish (US)
Pages (from-to)25-32
Number of pages8
JournalJournal of Neuroimmunology
Volume251
Issue number1-2
DOIs
StatePublished - Oct 15 2012

Keywords

  • Dendritic cells
  • Fas ligand
  • Genetic engineering
  • Guided Missile
  • Myasthenia gravis
  • Specific immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Specific immunotherapy of experimental myasthenia gravis in vitro and in vivo: The Guided Missile strategy'. Together they form a unique fingerprint.

Cite this